Key points from article :
Gallant Therapeutics, a company developing stem cell therapies for pets, raised $15 million to advance their treatments.
Their lead candidate targets Feline Chronic Gingivostomatitis, a painful mouth disease in cats.
They also have therapies in development for osteoarthritis, chronic kidney disease, and skin allergies in dogs and cats.
This funding will help them get FDA approval for their first treatment and develop others.
They use stem cells from healthy donors, making their treatments readily available.
This investment could revolutionise pet healthcare by offering new treatment options for common diseases.
